Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Account Payables: 2016-2025

Historic Change in Account Payables for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to -$8.8 million.

  • Akebia Therapeutics' Change in Account Payables fell 191.16% to -$8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.9 million, marking a year-over-year decrease of 763.49%. This contributed to the annual value of -$1.4 million for FY2024, which is 73.99% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Change in Account Payables of -$8.8 million as of Q3 2025, which was down 336.99% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Change in Account Payables ranged from a high of $18.9 million in Q4 2022 and a low of -$13.8 million during Q3 2021.
  • In the last 3 years, Akebia Therapeutics' Change in Account Payables had a median value of -$2.2 million in 2025 and averaged -$1.3 million.
  • In the last 5 years, Akebia Therapeutics' Change in Account Payables crashed by 272.51% in 2021 and then spiked by 491.65% in 2022.
  • Over the past 5 years, Akebia Therapeutics' Change in Account Payables (Quarterly) stood at $3.2 million in 2021, then surged by 491.65% to $18.9 million in 2022, then tumbled by 76.20% to $4.5 million in 2023, then slumped by 46.84% to $2.4 million in 2024, then slumped by 191.16% to -$8.8 million in 2025.
  • Its Change in Account Payables stands at -$8.8 million for Q3 2025, versus $3.7 million for Q2 2025 and -$2.2 million for Q1 2025.